Orphan Drugs & Rare Diseases Conference, 8-9 October 2012, London, UK

Date: Aug-20-2012SMi is delighted to welcome: Carlos Camozzi, Vice President & Chief Medical Officer at uniQure, to their inaugural Orphan Drugs & Rare Diseases conference on 8th & 9th October 2012 in London. Dr. Camozzi will be joining leading leaders in gene therapy and rare diseases.
As recently reported in Nature, UniQure have won recommendation to market the western world's first gene therapy, Glybera. The company's success is a huge step towards a long-cherished goal of gene therapy: delivering, in a single treatment, a life-long, functional copy of a missing gene to patients. 

Jorn Aldag, chief executive of UniQure, says that the announcement from the EMA is an "overdue signal" to the gene-therapy community that things are changing. "It unlocks the potential," he says, quoted in Nature. "You will see more investment coming."*

Perhaps as important is UniQure's pioneering "annuity" approach to reimbursement, staggering payments over the five years for which treatment has been proved to work. As highlighted by the Financial Times, such financial innovation may prove as important as the scientific breakthroughs that led to the treatment in the first place**.

Other keynote speakers presenting at this outstanding event include:

Geraldine Honnet, Head of Clinical Development, Généthon
Celine Plisson, Associate Medical Director, Orphan Europe Recordati Group
Gary Clements, Senior Director, Business Development, Shire 
Richard Philipson, Disease Area Head for Immuno / Inflammation, GlaxoSmithKline, Neurosciences MDC
Elisa Muscianisi, Medical Advisor, Bone, Inflammation & Rheumatology Areas, Novartis


Visit http://www.smi-online.co.uk/goto/orphandrugs-event34.asp to secure your place now! Alternatively, contact Alternatively Contact Fateja Begum on telephone +44 (0) 20 7827 6184 or email on fbegum@smi-online.co.uk

Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.